SCHEMBL298685

SCHEMBL298685

CCCS(=O)(=O)Nc1ccc(F)c(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)c1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.53
KIT P10721 2/20 0.53
BRAF P15056 8/20 0.45
CYP2C19 P33261 7/20 0.43
CYP3A4 P08684 6/20 0.43
CYP2D6 P10635 1/20 0.43
BMPR1B O00238 1/20 0.43
PLK4 O00444 1/20 0.43
PIR O00625 1/20 0.43
AURKA O14965 1/20 0.43
DCLK1 O15075 1/20 0.43
EPHB6 O15197 1/20 0.43
RIPK2 O43353 1/20 0.43
STK16 O75716 1/20 0.43
OXSR1 O95747 1/20 0.43
MAP4K4 O95819 1/20 0.43
ABL1 P00519 1/20 0.43
RAF1 P04049 1/20 0.43
LCK P06239 1/20 0.43
FYN P06241 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL295800 0.89 CSF1R (0.54) CSF1RKITBRAFCYP2C19CYP3A4
SCHEMBL299446 0.88 CYP2C19 (0.59) CSF1RKITBRAFCYP2C19CYP3A4
SCHEMBL30695622 0.88 CYP2C19 (0.59) CSF1RKITBRAFCYP2C19CYP3A4
SCHEMBL3708667 0.81 CSF1R (0.63) CSF1RKITCYP2C19CYP3A4CYP2D6
SCHEMBL1267738 0.80 CSF1R (0.69) CSF1RKITCYP2C19CYP3A4CYP2D6
SCHEMBL2382653 0.78 CSF1R (0.58) CSF1RKITCYP2C19CYP3A4CYP2D6
SCHEMBL1267391 0.76 CSF1R (0.63) CSF1RKITCYP2C19CYP3A4CYP2D6
SCHEMBL298247 0.75 CYP2C9 (0.57) BRAFCYP2C19CYP3A4CYP2D6RIPK2
SCHEMBL1267524 0.75 CSF1R (0.67) CSF1RKITCYP2C19CYP3A4CYP2D6
SCHEMBL1266824 0.74 CSF1R (0.69) CSF1RKITCYP2C19CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4295912-A2 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Daiichi Sankyo, Inc. (US) 2023-12-27 EP disclosed
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2019-08-29 US disclosed
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2017-08-31 US disclosed
US-9487515-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2016-11-08 US disclosed
US-9169250-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2015-10-27 US disclosed
US-20150265586-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR DAIICHI SANKYO, INC. 2015-09-24 US disclosed
US-20140243365-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR DAIICHI SANKYO, INC. 2014-08-28 US disclosed
US-8461169-B2 Compounds modulating c-fms and/or c-kit activity PLEXXIKON INC. (US) 2013-06-11 US disclosed
US-8404700-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2013-03-26 US disclosed
US-20120309756-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC 2012-12-06 US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 EP disclosed
US-20110230482-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY PLEXXIKON INC. 2011-09-22 US disclosed
US-20110230482-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY PLEXXIKON INC. 2011-09-22 US disclosed
US-7893075-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON, INC. (US) 2011-02-22 US disclosed
US-7893075-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON, INC. (US) 2011-02-22 US disclosed
US-7893075-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON, INC. (US) 2011-02-22 US disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 US disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 US disclosed
WO-2008064255-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 WO disclosed
WO-2008063888-A2 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON, INC. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243365-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CSF1R 4/4885KIT 1/4885BRAF 28/4885
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CSF1R 4/4885KIT 1/4885BRAF 28/4885
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor KIT, FLT3, FLT1 CSF1R 4/4885KIT 1/4885BRAF 28/4885
US-20120309756-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CSF1R 4/4885KIT 1/4885BRAF 28/4885
US-20110230482-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY KIT, FLT3, FER CSF1R 10/4885KIT 1/4885BRAF 12/4885
US-20150265586-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CSF1R 4/4885KIT 1/4885BRAF 28/4885
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 CSF1R 4/4885KIT 1/4885BRAF 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.